Literature DB >> 23018286

Ceramide expression and cell homeostasis in chronic obstructive pulmonary disease.

Maria C Scarpa1, Simonetta Baraldo, Emanuela Marian, Graziella Turato, Fiorella Calabrese, Marina Saetta, Piero Maestrelli.   

Abstract

BACKGROUND: Increased expression of ceramide has been detected in emphysema. Ceramide promotes autophagy and apoptosis, which concur with cellular homeostasis.
OBJECTIVES: To determine whether ceramide expression is associated with the development of chronic obstructive pulmonary disease (COPD) and with altered cellular homeostasis in lung parenchyma.
METHODS: We studied 10 subjects with severe COPD, 13 with mild/moderate COPD, 11 with idiopathic pulmonary fibrosis (IPF), 12 non-COPD smokers, and 11 nonsmoking controls. The immunoreactivity for ceramide along with markers of autophagy (LC3B), apoptosis (cleaved caspase-3), and cell proliferation (MIB1) was quantified in alveolar walls.
RESULTS: Ceramide expression was increased in COPD patients compared with control smokers and was related to the impairment of gas exchange but not to the degree of airflow limitation. In COPD, an important activation of apoptosis and autophagy pathways was observed, particularly in patients with severe disease, that was not counterbalanced by cell proliferation. Upregulation of ceramide was observed even in subjects with IPF in whom activation of apoptosis and autophagy was negligible and cell proliferation was instead the most prominent feature.
CONCLUSIONS: Ceramide expression, which is increased in COPD and even more so in IPF, appears to be neither specific nor related to COPD severity, probably representing a broader marker of lung damage. In contrast, apoptosis and autophagy are characteristics of the COPD pathology, particularly in its most severe stage.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23018286     DOI: 10.1159/000341185

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  14 in total

1.  Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes.

Authors:  Russell P Bowler; Sean Jacobson; Charmion Cruickshank; Grant J Hughes; Charlotte Siska; Daniel S Ory; Irina Petrache; Jean E Schaffer; Nichole Reisdorph; Katerina Kechris
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

2.  Ceramide and sphingosine-1 phosphate in COPD lungs.

Authors:  Evgeny V Berdyshev; Karina A Serban; Kelly S Schweitzer; Irina A Bronova; Andrew Mikosz; Irina Petrache
Journal:  Thorax       Date:  2021-01-29       Impact factor: 9.102

3.  Ceramide as a mediator of non-alcoholic Fatty liver disease and associated atherosclerosis.

Authors:  Takhar Kasumov; Ling Li; Min Li; Kailash Gulshan; John P Kirwan; Xiuli Liu; Stephen Previs; Belinda Willard; Jonathan D Smith; Arthur McCullough
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

4.  Lipid Analysis of Airway Epithelial Cells for Studying Respiratory Diseases.

Authors:  Nicole Zehethofer; Saskia Bermbach; Stefanie Hagner; Holger Garn; Julia Müller; Torsten Goldmann; Buko Lindner; Dominik Schwudke; Peter König
Journal:  Chromatographia       Date:  2014-11-07       Impact factor: 2.044

Review 5.  Sphingolipids as cell fate regulators in lung development and disease.

Authors:  Joyce Lee; Behzad Yeganeh; Leonardo Ermini; Martin Post
Journal:  Apoptosis       Date:  2015-05       Impact factor: 4.677

6.  Exploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease.

Authors:  Hoang Kim Tu Trinh; Su-Chin Kim; Kumsun Cho; Su-Jung Kim; Ga-Young Ban; Hyun-Ju Yoo; Joo-Youn Cho; Hae-Sim Park; Seung-Hyun Kim
Journal:  Sci Rep       Date:  2016-11-10       Impact factor: 4.379

7.  Plasma sphingolipids in HIV-associated chronic obstructive pulmonary disease.

Authors:  Shane Hodgson; Timothy J Griffin; Cavan Reilly; Stephen Harvey; Bruce A Witthuhn; Brian J Sandri; Ken M Kunisaki; Chris H Wendt
Journal:  BMJ Open Respir Res       Date:  2017-04-03

8.  Neutral sphingomyelinase-2, acid sphingomyelinase, and ceramide levels in COPD patients compared to controls.

Authors:  Simon R Lea; Hannah J Metcalfe; Jonathan Plumb; Christian Beerli; Chris Poll; Dave Singh; Katharine H Abbott-Banner
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-09-06

9.  Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics.

Authors:  Feng Yan; Zhensong Wen; Rui Wang; Wenling Luo; Yufeng Du; Wenjun Wang; Xianyang Chen
Journal:  BMC Pulm Med       Date:  2017-12-06       Impact factor: 3.317

Review 10.  The Role of S1P and the Related Signaling Pathway in the Development of Tissue Fibrosis.

Authors:  Erjin Wang; Xingxuan He; Ming Zeng
Journal:  Front Pharmacol       Date:  2019-01-08       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.